By Ulrike Dauer
Shareholders of Sigma-Aldrich Corp. on Friday approved the
acquisition by German pharmaceutical and chemical company Merck
KGaA, both companies said.
At a special meeting in St. Louis, Mo., where Sigma-Aldrich is
headquartered, about 78% of the company's shareholders voted in
favor of the proposed transaction.
Merck said it still expects the deal to close in mid-2015.
Shareholders also approved, on a non-binding basis, compensation
that may become payable to named executive officers as a result of
the acquisition.
The board of directors of the U.S. life science company approved
the transaction in September. Under the deal, Merck KGaA will
acquire Sigma-Aldrich for $140.00 per share in cash.
The transaction still awaits regulatory approvals.
--Write to Ulrike Dauer at ulrike.dauer@wsj.com
Access Investor Kit for Merck KGaA
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=DE0006599905
Access Investor Kit for Merck KGaA
Visit
http://www.companyspotlight.com/partner?cp_code=P479&isin=US5893391004
Subscribe to WSJ: http://online.wsj.com?mod=djnwires